Effects of tacrolimus (FK506) on induction of glutathione S-transferase P-positive foci and liver cell regeneration after partial hepatectomy in F344 rats

Hepatology Research

Volumn 10, Issue 1, 1998, Pages 58-65

  Ohnishi, Takamasa ^a   Yogita, Shiro ^a   Tashiro, Seiki ^a   Chone, Yoshifumi ^a   Kitaura, Keisuke ^a   Hino, Akiko ^a   Izumi, Keisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 Bromo 2 deoxyuridine; Hepatocarcinogenesis; Hepatocyte growth factor; Medium term liver bioassay

Indexed keywords

BROXURIDINE; GLUTATHIONE TRANSFERASE; SCATTER FACTOR; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL PROLIFERATION; CONTROLLED STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER REGENERATION; LIVER WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT;

EID: 0031932424     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(97)00101-0     Document Type: Article

References (23)

1. Kino T., Hatanaka H., Hashimoto M. et al. FK506, a novel immunosuppressant isolated from Streptomyces. J Antibiot. 40:1987;1249-1255.
2. Tocci M.J., Matkovich D.A., Collier K.A. et al. The immunosuppressant FK506 selectively inhibits expression of early T-cell activation genes. J Immunol. 143:1989;718-726.
3. Granelli-Piperno A., Nolan P., Inaba K., Steinman R.M. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med. 172:1990;1869-1872.
4. Francavilla A., Barone M., Todo S., Zeng Q., Porter K.A., Starzl T.E. Augmentation of rat liver regeneration by FK506 compared with cyclosporin. Lancet. 25:1989;1248-1249.
5. Okamura N., Tsukada K., Sakaguchi T., Ohtake M., Yoshida K., Muto T. Enhanced liver regeneration by FK506 can be blocked by interleukin-1α and interleukin-2. Transplant Proc. 24:1992;413-415.
6. Sato Y., Tsukada K., Yoshida K., Muto T., Matumoto Y. FK506 suppresses class II antigen expression in regenerating livers following PH in the rat. Transplant Proc. 24:1992;1628-1630.
7. Kitahara S., Makuuchi S., Kawasaki S., Ishizone S., Matsunami H. Lymphoproliferative disorders after FK506. Lancet. 337:1991;1234.
8. Kardry Z., Bronsther O., Thiel D.H., Randhawa P., Fung J.J., Starzl T.E. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant. 7:1993;188-194.
9. Ito N., Tsuda H., Tatematsu M. et al. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats: an approach for a new medium-term bioassay system. Carcinogenesis. 9:1988;387-394.
10. Ito N., Hasegawa R., Imaida K., Hirose M., Shirai T. Medium-term liver and multi-organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Exp Toxicol Pathol. 48:1996;113-119.
11. Higgins G.M., Anderson R.M. Experimental pathology of the liver; restoration of the liver of the white rat following partial surgical removal. Arch Pathol. 12:1931;186-202.
12. Penn I. Cancers following cyclosporine therapy. Transplant. 43:1987;32-35.
13. Yu Y., Yuzawa K., Otsuka M., Fukao K. Mutagenicity of the new immunosuppressive drugs, FK506 and spergualin. Transplant Proc. 25:1993;2116-2118.
14. Shinozuka H., Warty V.S., Masuhara M., Murase N., Iwatsuki S. Effect of FK506 on experimental liver carcinogenesis. Transplant Proc. 23:1991;3197-3199.
15. Jiang H., Yamamoto S., Nishikawa K., Kato R. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis. 14:1993;67-71.
16. Mazzaferro V., Scotti-Foglieni C.L., Porter K.A. et al. Studies of the hepatotrophic qualities of FK506 and Cy A. Transplant Proc. 22:1990;93-95.
17. Tanaka N., Yamamoto H., Tatemoto A., Urabe T., Orita K. Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK506. Int. J Immunopharmacol. 15:1993;211-218.
18. Francavilla A., Starzl T.E., Barone M. et al. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK506. Hepatology. 14:1991;140-143.
19. Ishiki Y., Ohnishi H., Muto Y., Matsumoto K., Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent anti-hepatitis effect in vivo. Hepatology. 16:1992;1227-1235.
20. Yaono M., Hasegawa R., Mizoguchi Y. et al. Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N-ethyl-N-hydroxyethylnitrosamine. Jpn J Cancer Res. 86:1995;718-723.
21. Noji S., Tashiro K., Koyama E. et al. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun. 173:1990;42-47.
22. Tojimbara T., Bermudez L.E., Egawa H., Hayashi M., So S.K., Esquivel C.O. Cyclosporine and tacrolimus both suppresses activation of Kupffer cells in vitro. Transplant Proc. 28:1996;1381-1382.
23. Izumi K., Sano N., Otsuka H., Kinouchi T., Ohnishi Y. Tumor promoting potential in male F344 rats and mutagenicity in Salmonella typhimurium of dipyrone. Carcinogenesis. 12:1991;1221-1225.